The Ocular Genomics Institute was well represented at the 2024 Iser meeting in Buenos Aires Argentina
October 31, 2024The following OGI members made presentations: Ayellet Segre PhD: GWAS and Transcriptomics riven drug repurposing for glaucoma Read More
Anil Chekuri Receives 2024 Iraty Award for Research in Retinal Diseases
October 31, 2024OGI investigator Anil Chekuri of the Grousbeck Gene Therapy Center and the Vandenberghe lab, is the 2024 Iraty Award which pays tribute to the life and work of Dr. Charles Schepens. The prize money will be used to support Anil's research, which aims to develop gene therapy to rescue retinal ganglion cell loss in familial dysautonomia Read More
Eric Pierce presents Lerner Lecture at Cleveland Clinic
October 31, 2024Eric Pierce MD PhD OGI director Eric Pierce presented ongoing research on the genetics of and the genetic therapies for inherited retinal degenerations at the 24th Lerner Lecture at the Cleveland Clinic in July. This prestigious lecture honors the late Chairman of the Cleveland Clinic Board. Previous Recipients have included eight Nobel... Read More
Gene Therapy Keynote speaker Eric Pierce
October 10, 2024Eric Pierce, director of the OGI will be the keynote speaker at the ARVO conference on Frontiers in Ocular Gene Therapy Research Conference. He will discuss the latest advancements, key challenges and future directions of gene therapy research for ophthalmic diseases and disorders. Read More
Genetic Finding leads to new hypotheses for treatment of Central Serous Chorioretinopathy.
September 27, 2024Elizabeth Rossin https://www.sciencedirect.com/science/article/abs/pii/S0002939424004082?dgcid=author
OGI Clinician Scientists recognized for excellence in clinical care and research
July 23, 2024Rachel Huckfeldt MD, PhD is among the 2024 honorees for the Anne Klibanski Visiting Scholars Award. This award is presented to women faculty clinicians, educators, researchers, and postdoctoral fellows who have demonstrated exceptional promise as leaders in their... Read More
OGI investigators validate new technique to predict pathogenic variants associated with inherited retinal disease
June 11, 2024Advances in gene sequencing technologies have accelerated the identification of genetic variants, but better tools are needed to understand which are causal of disease. This would be particularly useful in fields where gene therapy is a potential therapeutic modality for a disease-causing variant such as inherited retinal disease (IRD). Read More
CRISPR Gene Editing shown to be effective in improving vision
May 20, 2024Boston, Mass. — Results from a groundbreaking clinical trial of CRISPR gene editing in 14 individuals with a form of inherited blindness show that the treatment is safe and led to measurable improvements in 11 of the participants treated. The phase 1/2 trial called BRILLIANCE, was led by principal investigator Read More
Knights Templar Eye Foundation 2024- 2025 Career Starter Grants
May 2, 2024Ocular Genomics Institute members Hanmeng Zhang, Egle Galdikatie-Braziene, and Kannan Manian were awarded support for their work. Hanmeng Zhang, PhD: Investigating the role of Oxidative DNA... Read More
Dr. Ryoji Amamoto receives Child Health Research Grant Award from the Charles H. Hood foundation.
January 29, 2024Ryoji Amamoto, PhD, an Assistant Scientist in the Department of Ophthalmology, has been selectedto receive a Child Health Research Grant Award fromthe Charles H. Hood Foundation. These highly competitive awards provide $200,000 over two years to support scientific research and advance the careers of promising scientists at premier New... Read More
Inas Aboobakar, M.D – K23 clinician-scientist grant recipient.
January 29, 2024Dr. Inas Aboobakar of the Wiggs lab received a K23 clinician-scientist grant from the National Eye Institute. With this grant, Dr. Aboobakar will investigate the clinical impact and underlying disease mechanisms for glaucoma-associated genes that function in the mitochondria, the energy-producing parts of cells. This work is designed to help pave... Read More